Dexcom Inc Stock Revenue
| DXCM Stock | USD 80.91 1.60 2.02% |
DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 3.6 B | 3.8 B |
DexCom | Revenue |
DexCom Inc Company Revenue Analysis
DexCom's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current DexCom Revenue | 3.62 B |
Most of DexCom's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of DexCom
Projected quarterly revenue analysis of DexCom Inc provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of DexCom match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in DexCom's stock price.
DexCom Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as Revenue. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.
| 0.81 | 0.84 | 0.05 | 0.81 | -0.05 | ||
| 0.81 | 1.0 | -0.26 | 1.0 | 0.3 | ||
| 0.84 | 1.0 | -0.25 | 1.0 | 0.29 | ||
| 0.05 | -0.26 | -0.25 | -0.27 | -1.0 | ||
| 0.81 | 1.0 | 1.0 | -0.27 | 0.31 | ||
| -0.05 | 0.3 | 0.29 | -1.0 | 0.31 |
Click cells to compare fundamentals
DexCom Revenue Historical Pattern
Today, most investors in DexCom Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DexCom's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of DexCom revenue as a starting point in their analysis.
DexCom Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
DexCom Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, DexCom Inc reported 3.62 B of revenue. This is 52.51% lower than that of the Health Care Equipment & Supplies sector and 42.01% higher than that of the Health Care industry. The revenue for all United States stocks is 61.61% higher than that of the company.
DexCom Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is currently under evaluation in revenue category among its peers.
DexCom ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.Environmental | Governance | Social |
DexCom Institutional Holders
Institutional Holdings refers to the ownership stake in DexCom that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of DexCom's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DexCom's value.| Shares | Wellington Management Company Llp | 2024-09-30 | 5.7 M | Jpmorgan Chase & Co | 2024-09-30 | 5.6 M | Amvescap Plc. | 2024-09-30 | 5.5 M | Norges Bank | 2024-06-30 | 5.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.3 M | Bank Of New York Mellon Corp | 2024-09-30 | 4.8 M | American Century Companies Inc | 2024-09-30 | 4 M | Amundi | 2024-09-30 | 3.8 M | Northern Trust Corp | 2024-09-30 | 3.4 M | Vanguard Group Inc | 2024-09-30 | 47.4 M | Blackrock Inc | 2024-06-30 | 34.5 M |
DexCom Fundamentals
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 31.08 B | ||||
| Shares Outstanding | 390.6 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 97.16 % | ||||
| Number Of Shares Shorted | 9.12 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 15.65 X | ||||
| Price To Sales | 7.99 X | ||||
| Revenue | 3.62 B | ||||
| Gross Profit | 1.88 B | ||||
| EBITDA | 916.7 M | ||||
| Net Income | 541.5 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 5.07 X | ||||
| Cash Flow From Operations | 748.5 M | ||||
| Short Ratio | 1.86 X | ||||
| Earnings Per Share | 1.65 X | ||||
| Price To Earnings To Growth | 1.24 X | ||||
| Target Price | 95.26 | ||||
| Number Of Employees | 9.5 K | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 31.6 B | ||||
| Total Asset | 6.26 B | ||||
| Retained Earnings | 1.02 B | ||||
| Working Capital | 2.87 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
| Net Asset | 6.26 B |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out DexCom Piotroski F Score and DexCom Altman Z Score analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.